Hepatitis C Virus genotype testing helps guide treatment decisions by identifying the specific HCV genotype involved in infection.
One critical area of focus in our mission is Hepatitis C Virus (HCV) Genotype Testing. HCV is a viral infection that can lead to chronic liver disease and other serious health complications. Understanding the specific genotype of HCV a patient is infected with is essential for guiding treatment decisions, as different genotypes respond differently to antiviral medications.
Genotype testing allows healthcare providers to personalize treatment plans by selecting the most effective antiviral medications based on the patient's specific HCV genotype.
Tailored treatment can lead to higher cure rates and better patient outcomes, reducing the risk of disease progression and transmission.
Accurate genotype testing aids in identifying potential sources of infection, helping prevent further transmission.
Genient Technologies offers state-of-the-art solutions for HCV Genotype Testing.
We provide diagnostic tools and assays that accurately determine the HCV genotype, enabling precise treatment decisions.
Genient supports ongoing research efforts to better understand HCV genotypes, drug resistance patterns, and emerging variants.
We are dedicated to addressing the global burden of HCV by supporting access to accurate genotype testing in high-prevalence regions.
Genient Technologies is your trusted partner in the fight against Hepatitis C, working to improve healthcare outcomes, enhance patient experiences, and contribute to global health through HCV Genotype Testing solutions.
Genient Technologies offers HCV genotyping and drug-resistance solutions aligned with DeepChek® assays from ABL Diagnostics. The portfolio includes HCV typing assays and targeted drug-resistance assays for NS5A, NS3, and NS5B.
Choose from HCV typing-focused assays and drug-resistance panels based on the target region and laboratory workflow.
A research-use HCV genotyping assay focused on NS5B / 5'UTR amplification from plasma or serum RNA, with Sanger and NGS workflow compatibility.
View Details
A research-use HCV CORE genotyping assay for PCR amplification from plasma or serum RNA, compatible with Sanger and NGS workflows.
View Details
A research-use HCV NS5A genotyping and drug-resistance assay for PCR amplification from plasma or serum RNA, compatible with Sanger and NGS workflows.
View Details
A research-use HCV NS3 genotyping and drug-resistance assay for PCR amplification from plasma or serum RNA, compatible with Sanger and NGS workflows.
View Details
A research-use HCV NS5B genotyping and drug-resistance assay for PCR amplification from plasma or serum RNA, compatible with Sanger and NGS workflows.
View Details
Our team can help map target region, resistance objective, sequencing platform, and software requirements to the right HCV assay path.
Talk To Us
Designed for molecular laboratories that need HCV target-region coverage across amplification, sequencing, analysis, and reporting touchpoints.
Portfolio options cover NS5B / 5'UTR, CORE, NS5A, NS3, and NS5B target regions.
The source assays are positioned as compatible with both Sanger and next-generation sequencing workflows.
DeepChek HCV software/module references are included so laboratories can discuss analysis workflow needs clearly.
Speak with Genient Technologies for assay selection, availability, workflow fit, and implementation support.
Contact Us